MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:30Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Aldosterone antagonists]]
			[[Category:Potassium-sparing diuretics]]
			[[Category:Antiandrogens]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #52

2026-05-23T03:34:50Z

parser-claude batch MedTemplate pre-fill, Top 300 #52

New page

{{MedTemplate
| generic = Spironolactone
| brand = Aldactone, CaroSpir
| structure =
| classes = [[:Category:Aldosterone_antagonists|Mineralocorticoid (aldosterone) receptor antagonist]], [[:Category:Potassium-sparing_diuretics|Potassium-sparing diuretic]], [[:Category:Antiandrogens|Antiandrogen]]
| uses = <vote slug="hfref-use">Heart failure with reduced ejection fraction</vote>, <vote slug="primary-aldosteronism-use">Primary aldosteronism</vote>, <vote slug="cirrhotic-ascites-use">Ascites in cirrhosis</vote>, <vote slug="resistant-hypertension-use">Resistant hypertension</vote>, <vote slug="hirsutism-acne-use">Hirsutism / hormonal acne (off-label)</vote>
| starting_dose = 25 mg PO once daily for HFrEF and primary aldosteronism; up to 100 mg/d for ascites; 50-200 mg/d for hirsutism
| preparations = 25 mg, 50 mg, 100 mg tablets; 25 mg/5 mL oral suspension (CaroSpir)
| fda_max = 400 mg/d (acute primary aldosteronism diagnosis); 100-200 mg/d typical chronic
| pill_id =
| routes = Oral
| onset = Natriuresis at 2-3 days; endocrine effects (gynecomastia, antiandrogen action) over weeks
| duration = Variable; biologically active metabolite carries effect beyond plasma half-life
| halflife = 1.4 hours (parent); 13-24 hours for active metabolite canrenone<ref name="aldactone-label">FDA Prescribing Information, Aldactone (spironolactone), Pfizer, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/012151s075lbl.pdf</ref>
| bioavailability = ~70% (oral; bioavailability and absorption are improved with food)<ref name="aldactone-label" />
| pregnancy = Avoid in pregnancy; antiandrogen effects can feminize a male fetus.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="spironolactone-mech-claim">Spironolactone is a competitive antagonist of the mineralocorticoid receptor; blocking aldosterone-driven transcription in collecting-duct principal cells decreases epithelial sodium channel (ENaC) and Na+/K+ ATPase activity, producing natriuresis with potassium and proton retention.</vote> At higher concentrations it also binds the androgen receptor (antiandrogen) and the progesterone receptor (PR partial agonism), accounting for gynecomastia, breast tenderness, antiandrogen efficacy in hirsutism/acne, and menstrual irregularity. RALES (1999) established the mortality benefit in severe HFrEF that defines its modern HF role<ref name="aldactone-label" />.
}}

== References ==
<references />

Spironolactone - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #52